← Eichor
Study identifier: NCT04894188 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

Condition: Prostate Cancer  ·  Sponsor: National Taiwan University Hospital

PhaseNA
Planned participants38
Who can joinMale, 20 Years to 75 Years
Healthy volunteersNo

About this study

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy can fight prostate cancer by androgen deprivation. It is not yet known if neoadjuvant radiation therapy is a more effective therapy for high-risk prostate cancer. PURPOSE: Two-stage randomized trial to compare the effectiveness and safety of neoadjuvant radiotherapy and hormone therapy followed by radical prostatectomy in men with high-risk locally advanced prostate cancer

This description comes directly from the study's public registry record.

Talk to the study team

Chi-Shin Tseng, MD  ·  +886223123456  ·  clifford1987tcs@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

National Taiwan University Hospital Yunlin BranchDouliu City/Huwei Township, Yunlin County, TaiwanRecruiting
National Taiwan University HospitalTapiei, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04894188